Sharing Supply-Chain Security - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sharing Supply-Chain Security
A panel of industry and regulatory experts, including FDA, discuss efforts to secure the global pharmaceutical supply chain. This article contains bonus online-exclusive material.


Pharmaceutical Technology
Volume 33, Issue 11

Tom Buggy on Europe's audit program


Tom Buggy, PhD
Buggy is international quality manager of DSM Anti-Infectives in The Netherlands and part of the Quality Working Group of the European Chemical Industry Council's Active Pharmaceutical Ingredients Committee (APIC). He is also a key member of the APIC Audit Program Task Force.


Figure 1: The APIC compliance triangle. QP is qualifed person. (FIGURE IS COURTESY OF T. BUGGY)
As the European API manufacturers association, APIC fully understands the risks to patients if non-GMP or counterfeit APIs are used as starting materials in the manufacture of medicinal products. We recognize the importance of supplier qualification as an effective quality system to approve new suppliers and to periodically evaluate suppliers and manufacturers for ongoing manufacture. In fact, APIC is preparing a supplier-qualification guidance that should be published in November 2009.

One key element we've been dealing with at APIC in terms of supplier qualifications is the on-site audit. When you look at the overall audit requirements in the pharmaceutical industry and the international requirements ... the audit burden on the industry is overpowering. APIC has developed a third-party audit program... that is available for the pharmaceutical industry to use whenever they see the need for a third-party audit that can be shared with many medicinal-product manufacturers (see Figure 1). The option of a credible independent third-party audit is acceptable to the European authorities as long as certain principles are followed. Key elements of the APIC audit program are:
  • Coordination of the audits by the API Compliance Institute to avoid any potential conflict of interest with APIC members
  • A standardized six-step procedure for performing the third-party audit
  • A standard approach for an audit of an API manufacturer, which involves two days with two auditors to make sure there is an effective assessment of GMP compliance
  • Most importantly, only APIC-certified auditors are involved.

With regard to auditors, they must have a good background in terms of qualification in chemistry or a related science and appropriate experience in the pharmaceutical industry. To become an APIC-certified auditor, the individual must pass a five-day course covering the GMP requirements for APIs, including a workshop on auditing techniques related to APIs. The API Compliance Institute ensures that the auditors chosen to perform the audit are independent of the customer and the auditee to avoid potential conflicts of interest. Auditors must also sign a confidentiality agreement.

Auditors [assess] GMP compliance based on the International Conference on Harmonization Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients guideline. Any findings that come out of the audit are explained in full in the closing meeting with the auditee. The auditors classify the findings using a similar classification system used by the European member-state inspectors and include detailed evidence for their findings in the audit reports. At the end of the audit, there will be a clear indication whether the GMP-compliance level has been assessed as satisfactory by the auditors. The APIC audit report can also be shared with other medicinal-product manufacturers.

The key advantage of the APIC audit program is that it is based on the guidances of the European authorities relating to third-party audits. We think this audit program can contribute significantly to assessing overall supply-chain security of medicines for the protection of patients. We also agree that the program provides only one option for effective audits. If the industry as a whole can work together, we can do more to ensure the safety and integrity of the medicines used worldwide.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here